Details for Patent: 11,918,557
Which drugs does patent 11,918,557 protect, and when does it expire?
Patent 11,918,557 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has one hundred and fifty-three patent family members in twenty-three countries.
Summary for Patent: 11,918,557
| Title: | Treatment of circadian rhythm disorders |
| Abstract: | Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
| Inventor(s): | Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos |
| Assignee: | Vanda Pharmaceuticals Inc |
| Application Number: | US18/183,655 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,918,557 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 11,918,557
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE | 205677 | Jan 31, 2014 | RX | Yes | 11,918,557 | ⤷ Start Trial | U-3003 | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE | 205677 | Jan 31, 2014 | RX | Yes | 11,918,557 | ⤷ Start Trial | U-3865 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION | 214517 | Dec 1, 2020 | RX | Yes | 11,918,557 | ⤷ Start Trial | U-3003 | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,918,557
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 11,918,557 | ⤷ Start Trial | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Start Trial | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 11,918,557 | ⤷ Start Trial | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON | ⤷ Start Trial | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,918,557 | ⤷ Start Trial | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,918,557
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013211878 | ⤷ Start Trial | |||
| Australia | 2013211880 | ⤷ Start Trial | |||
| Australia | 2013361459 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
